Resonance HealthASX:RHT +4.55% OCF Margin % is 2.17% as of Dec. 2025, which is 82% below its 10-year median of 12.17. The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Resonance Health ranks worse than 67.37% on this metric.
The historical rank and industry rank for Resonance Health's OCF Margin % or its related term are showing as below:
ASX:RHT'
s OCF Margin % Range Over the Past 10 Years
Min: -38.01 Med: 12.17 Max: 44.55
Current: 3.04
During the past 13 years, the highest OCF Margin % of Resonance Health was 44.55%. The lowest was -38.01%. And the median was 12.17%.
ASX:RHT's OCF Margin % is ranked worse than 67.37% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 8.28
vs ASX:RHT: 3.04
Resonance Health OCF Margin % Related Terms
Resonance Health OCF Margin % Historical Data
* Premium members only.
The historical data trend for Resonance Health's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, TEM: OCF Margin % Comparison
For the Health Information Services subindustry, Resonance Health's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health OCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Resonance Health's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a OCF Margin % of 2.17% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Resonance Health and its competitors. This is 82% below median its historical median of 12.17. According to the industry distribution chart, Resonance Health ranks #450 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 67.4%.
Is Resonance Health's OCF Margin % too high?
Resonance Health's current OCF Margin % of 2.17% is 82% below median its 10-year median of 12.17. The Healthcare Providers & Services industry median OCF Margin % is 8.28. Resonance Health's value of 2.17% is 73.8% below this industry median. Based on the distribution chart, Resonance Health ranks #450 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does Resonance Health's OCF Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #450 out of 668 companies for OCF Margin %. This places Resonance Health in the lower half of its industry. The industry median OCF Margin % is 8.28. Resonance Health's value of 2.17% is 73.8% below this benchmark. While the company's 10-year median is 12.17 vs. the industry median of 8.28, Resonance Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Healthcare Providers & Services company?
The median OCF Margin % among Healthcare Providers & Services companies is 8.28, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current OCF Margin % of 2.17% is 73.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median OCF Margin % is 8.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current OCF Margin % is 2.17%, which is 82% below median its own 10-year median of 12.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current OCF Margin % is 2.17%, which is 82% below median its 10-year median of 12.17 and 73.8% below the Healthcare Providers & Services industry median of 8.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current OCF Margin % is 2.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 